Apogee Therapeutics (APGE) Projected to Post Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($1.19) per share for the quarter.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). On average, analysts expect Apogee Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apogee Therapeutics Trading Down 0.9 %

Shares of NASDAQ APGE traded down $0.31 during trading hours on Wednesday, reaching $35.26. The stock had a trading volume of 702,231 shares, compared to its average volume of 520,767. Apogee Therapeutics has a fifty-two week low of $26.20 and a fifty-two week high of $63.50. The firm has a 50-day moving average of $36.00 and a 200-day moving average of $41.86. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -14.57 and a beta of 1.70.

Insider Buying and Selling

In related news, CEO Michael Thomas Henderson sold 10,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the sale, the chief executive officer now owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. This trade represents a 0.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Carl Dambkowski sold 3,860 shares of the business's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total transaction of $139,809.20. Following the transaction, the insider now owns 247,173 shares in the company, valued at $8,952,606.06. This represents a 1.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,450 shares of company stock worth $489,772 in the last three months. Insiders own 36.10% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on APGE shares. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Citigroup assumed coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $95.00 target price for the company. Finally, Wedbush reaffirmed an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $92.17.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.